Archives of osteoporosis · 2026
Zoledronic acid for chronic kidney disease-associated osteoporosis.
СтатьяКлинический случайНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Sakthivel Sukanya, Kjærgaard Krista Dybtved, Ivarsen Per, Langdahl Bente, Jørgensen Hanne Skou
Аннотация
BACKGROUND: Patients with chronic kidney disease have a high risk of fracture, but evidence-based treatment protocols for osteoporosis are lacking. Bisphosphonates are commonly used anti-resorptive drugs, but due to renal excretion, patients with chronic kidney disease have not been included in clinical trials.
CASE PRESENTATION: We present a case of severe bone fragility in a patient on long-term hemodialysis therapy where zoledronate was well-tolerated and provided clinical improvement.
CONCLUSION: This case highlights the potential role of bisphosphonates in chronic kidney disease-associated osteoporosis and the need for trials to establish the safety and efficacy of anti-resorptive drugs in this patient population.
CASE PRESENTATION: We present a case of severe bone fragility in a patient on long-term hemodialysis therapy where zoledronate was well-tolerated and provided clinical improvement.
CONCLUSION: This case highlights the potential role of bisphosphonates in chronic kidney disease-associated osteoporosis and the need for trials to establish the safety and efficacy of anti-resorptive drugs in this patient population.